99mTc-Radiolabelled peptides for tumour imaging: Present and future

Current Medicinal Chemistry

Volumn 17, Issue 24, 2010, Pages 2656-2683

  Bolzati, C ^a   Refosco, F ^a   Marchiani, A ^a,b   Ruzza, P ^a  

^a CNR   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

Peptide receptors; Radiolabelled peptides; Technetium; Tumour imaging

Indexed keywords

BOMBESIN RECEPTOR; CHOLECYSTOKININ RECEPTOR; DEPREOTIDE TC 99M; GASTRIN; LIPOCORTIN 5; MOLYBDENUM 99; NEUROPEPTIDE Y RECEPTOR; NEUROTENSIN RECEPTOR; SOMATOSTATIN RECEPTOR; SUBSTANCE P RECEPTOR; TECHNETIUM 99M; TETRAMER; VAPREOTIDE;

ARTICLE; ASTROCYTOMA; BLADDER TUMOR; BREAST TUMOR; CANCER DIAGNOSIS; CLINICAL TRIAL; COLORECTAL TUMOR; DIAGNOSTIC IMAGING; GLIOBLASTOMA; HUMAN; ISOTOPE LABELING; LUNG SMALL CELL CANCER; MELANOMA; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; PANCREAS TUMOR; POSITRON EMISSION TOMOGRAPHY; PROSTATE TUMOR; PROTEIN EXPRESSION; PROTEIN TARGETING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STOMACH TUMOR;

DIAGNOSTIC IMAGING; HUMANS; NEOPLASMS; RADIOPHARMACEUTICALS; TECHNETIUM;

EID: 77955622854     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710791859388     Document Type: Article

References (234)

1. Weiner, R.; Thakur, M. In Radionuclide peptide cancer therapy. Chinol M., Paganelli G., Eds., Taylor & Francis: New York (NY) 2006, 41-85.
2. Weiner, R.E.; Thakur, M.L. Radiolabeled peptides in diagnosis and therapy of oncological deseases. Appl. Radiat. Isotop., 2002, 57, 749-763.
3. Virgolini, I.; Traub, T.; Leimer, M.; Novotny, C.; Pangerl, T.; Ofluoglu, S.; Halvadjieva, E.; Smith-Jones, P.; Flores, J.; Li, S.R.; Angelberger, P.; Havlik, E.; Andreae, F.; Raderer, M.; Kurtaran, A.; Niederle, B.; Dubczak, R. New radiopharmaceuticals for receptor scintigraphy and radionuclide therapy. Q. J. Nucl. Med., 2000, 44, 50-58.
4. Virgolini, I.; Traub, T.; Novotny, C.; Leimer, M.; Fuger, B.; Li, S.R.; Patri, P.; Pangerl, T.; Angelberger, P.; Raderer, M.; Andreae, F.; Kurtaran, A.; Dudczak, R. New trends in peptide receptor radioligands. Q. J. Nucl. Med., 2001, 45, 153-159.
5. Benedetti, E.; Morelli, G.; Accardo, A.; Mansi, R.; Tesauro, D.; Aloj, L.; Morelli, G. Criteria for the desing and biological characterization of radiolabeled peptide based pharmaceuticals. Biodrugs, 2004, 18, 279-295.
6. Aloj, L.; Morelli, G. Design, synthesis and preclinical evaluation of radiolabeled peptides for diagnosis and therapy. Curr. Pharm. Des., 2004, 10, 3009-3031.
7. Eckelman, W.C.; Erba, P.A.; Schwaiger, M.; Wagner, H.N.J.; Alberto, R.; Mazzi, U. Postmeeting summary on the round table discussion at the Seventh International Symposium on technetium in chemistry and nuclear medicine held in Bressanone Nucl. Med. Biol., 2007, 34, 1-4.
8. Mahmood, A.; Limpa-Amara, N.; MacKenzie, J.D.; Zimmerman, R.E.; El Fakhri, G.; Moore, S.C.; Jones, A.G. In Proceedings of the Seventh International Symposium on Technetium in Chemistry and Nuclear Medicine. Mazzi U., Ed., SGEditoriali: Padova (Italy) 2006, 465-470.
9. Rowland, D.J.; Cherry, S.R. Small-animal preclinical nuclear medicine instrumentation and methodology. Semin. Nucl. Med., 2008,38:209-222
10. Del Guerra, A.; Belcari, N. State-of-the-art of PET, SPECT and CT for small animal imaging. Nucl. Instrum. Methods Phys. Res. Sect. A, 2007, 583, 119-124.
11. Mariani, G.; Bruselli, L.; Duatti, A. Is PET an advantage versus planar and SPECT Imaging? Eur. J. Nucl. Mol. Imaging, 2008, 35, 1560-1565
12. Wagner, H.N.Jr. From molecular imaging to molecular medicine. J. Nucl. Med., 2006, 47, 13N-39N.
13. Townsend, D.W. Dual-modality imaging: combining anatomy and function. J. Nucl. Med., 2008, 49, 938-955.
14. Buck, A.K.; Nekolla, S.; Ziegler, S.; Beer, A.; Krause B.J.; Herrmann, K.; Scheidhauer K.; Wester, H.J.; Rummery, E.J.; Schwaiger, M.; Drzezga, A. SPECT/CT. J. Nucl. Med., 2008, 49, 1305-1319.
15. Franc, B.L.; Acton, P.D.; Mari, C.; Hasegawa B.H. Small animal SPECT and SPECT-CT: important tools for preclinical investigation. J. Nucl. Med., 2008, 49: 1651-1663.
16. Garcia-Garayoa, E.; Schibli, R.; Schubiger, P. A. Peptides radiolabeled with Re-186/188 and Tc-99m as potential diagnostic and therapeutic agents. Nucl. Sci. Tech., 2007, 18, 88-100.
17. Okarvi, S.M. Peptide-based radiopharmaceuticals: future tools for diagnostic imaging of cancers and other diseases. Med. Res. Rev., 2004, 24, 357-397.
18. Dijkgraaf, I.; Boerman, O.C.; Oyen, W.J.; Corstens, F.H.; Gotthardt, M. Development and application of peptide-based radiopharmaceuticals. Anticancer Agents Med. Chem., 2007, 7, 543-551.
19. Fields, G.B. In Solid-Phase Peptide Synthesis. Methods in Enzymology, Vol. 289 Academic Press: New York, 1997.
20. Mankoff, D.A.; Link, J.M.; Linden, H.M.; Sundararajan, L.; Krohn, K.A. Tumor receptor imaging. J. Nucl. Med., 2008, 49, 149S-163S.
21. Lamberts, S.W.J.; Bakker, W.H.; Reubi, J.C.; Krenning, E.P. Somatostatin- receptor imaging in the localization of endocrine tumors. N. Engl. J. Med., 1990, 323, 1246-1249.
22. 111In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res., 1998, 58, 437-441.
23. Boerman, O.C.; Oyen, W.J.G.; Corstens, F.H.M. Radio-labeled receptor-binding peptides: a new class of radiopharmaceuticals. Semin. Nucl. Med., 2000, 30, 195-208.
24. Lugtenburg, P.J.; Lowenberg, B.; Valkema, R.; Oei, H.Y.; Lamberts, S.W.; Eijkemans, M.J.; van Putten, W.L.; Krenning, E.P. Somatostatin receptor scintigraphy in the initial staging of lowgrade non-Hodgkin's lymphomas. J. Nucl. Med., 2001, 42, 222- 229.
25. Seregni, E.; Chiti, A.; Bombardieri, E. Radionuclide imaging of neuroendocrine tumours: biological basis and diagnostic results. Eur. J. Nucl. Med., 1998, 25, 639-658.
26. 99mTc-based [Tyr3] octreotate analogue for the detection of somatostatin receptor-positive tumours: synthesis and preclinical results. Eur. J. Nucl. Med. Mol. Imaging, 2002, 29, 742-753.
27. 99mTc depreotide. Semin. Nucl. Med., 2002, 32, 92-96.
28. 99mTc-labelled radiopharmaceutical for imaging somatostatin receptor- positive tumours: first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives. Eur. J. Nucl. Med., 2000, 27, 1318-1325.
29. 111In- DTPA-D-Phe1-octreotide. Eur. J. Nucl. Med., 2000, 27, 628-637.
30. 3 as prosthetic groups for labeling amines and peptides: approaches with pre- and postconjugate labelling. Nucl. Med. Biol., 1998, 25, 621-631.
31. Rehfeld, J.F. Cholecystokinin. Best Pract. Res. Clin. Endocrinol. Metab., 2004, 18, 569-586.
32. Reubi, J.C.; Schaer, J.C.; Waser, B. Cholecystokinin (CCK)-A and CCK-B/gastrin receptors in human tumors. Cancer Res., 1997, 57, 1377-1386.
33. Behr, T.M.; Jenner, N.; Behe, M.; Angerstein, C.; Gratz, S.; Raue, F.; Becker, W. Radiolabeled peptides for targeting cholecystokinin- B/gastrin receptor-expressing tumors. J. Nucl. Med., 1999, 40, 1029-1044.
34. Reubi, J.C.; Waser, B.; Schaer, J.C.; Laederach, U.; Erion, J.; Srinivasan, A.; Schmidt, M. A.; Bugaj, J.E. Unsulfated DTPA- and DOTA-CCK analogs as specific high-affinity ligands for CCK-B receptor-expressing human and rat tissues in vitro and in vivo. Eur. J. Nucl. Med., 1998, 25, 481-490.
35. Borin, G.; Calderan, A.; Ruzza, P.; Moroder, L.; Gohring, W.; Boverman, G.; Wunsch, E. Synthesis of human [15-norleucine] little- gastrin-II and des-1-tryptophan-[12-norleucine]minigastrin-II. Biol. Chem. Hoppe-Seyler, 1987, 368, 1363-1372.
36. Behe, M.; Becker, W.; Gotthardt, M.; Angerstein, C.; Behr, T.M. Improved kinetic stability of DTPA-dGlu as compared with conventional monofunctional DTPA in chelating indium and yttrium: preclinical and initial clinical evaluation of radiometal labelled minigastrin derivatives. Eur. J. Nucl. Med. Mol. Imaging, 2003, 30, 1140-1146.
37. 111In -labelled minigastrin. Eur. J. Nucl. Med. Mol. Imaging, 2008, 35, 386-392.
38. 99mTc DTPA-CCK-8]: preparation and biodistribution studies in rats and rabbits. Nucl. Med. Biol., 2001, 28, 667-678.
39. Laverman, P.; Behe, M.; Oyen, W.J.G.; Willems, P.; Corstens, F.H.M.; Behr, T.M.; Boerman, O.C. Two technetium-99m-labeled cholecystokinin-8 (CCK8) peptides for scintigraphic imaging of CCK receptors. Bioconjugate Chem., 2004, 15, 561-568.
40. 2+ metal fragment labeled cholecystokinin- 8 (CCK8) peptide for CCK-2 receptors imaging: in vitro and in vivo studies. J. Pept. Sci., 2007, 13, 211-219.
41. 99mTc-Tricarbonyl. Biopolymers, 2008, 90, 707-712.
42. Said, S.I.; Mutt, V. Polypeptide with broad biological activity - isolation from small intestine. Science, 1970, 169, 1217-1218.
43. Schwartz, C.J.; Kimberg, D.V.; Sheerin, H.E.; Field, M.; Said, S.I. Vasoactive intestinal peptide stimulation of adenylate cyclase and active electrolyte secretion in intestinal-mucosa. J. Clin. Invest., 1974, 54, 536-544.
44. Reubi, J. C. In vitro identification of VIP receptors in human tumors: potential clinical application. Ann. N.Y. Acad. Sci., 1996, 805, 753-759.
45. Fischman, A.J.; Babich, J.W.; Strauss, H.W. A ticket to ride - Peptide radiopharmaceuticals. J. Nucl. Med., 1993, 34, 2253-2263.
46. Virgolini, I.; Raderer, M.; Kurtaran, A.; Angelberger, P.; Yang, Q.; Radosavljevic, M.; Leimer, M.; Kaserer, K.; Li, S.R.; Kornek, G.; Hubsch, P.; Niederle, B.; Pidlich, J.; Scheithauer, W.; Valent, P. 123I-vasoactive intestinal peptide (VIP) receptor scanning: update of imaging results in patients with adenocarcinomas and endocrine tumors of the gastrointestinal tract. Nucl. Med. Biol., 1996, 23, 685-692.
47. Virgolini, I.; Raderer, M.; Kurtaran, A.; Angelberger, P.; Banyai, S.; Yang, Q.; Li, S.; Banyai, M.; Pidlich, J.; Niederle, B.; Scheithauer, W.; Valent, P. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N. Engl. J. Med., 1994, 331, 1116-1121.
48. 99mTclabeled vasoactive intestinal peptide analog for rapid localization of tumors in humans. J. Nucl. Med., 2000, 41, 107-110.
49. Lister-James, J.; Virgolini, I.; Nelson, C.A.; Pearson, D.A.; Leimar, M.; Moyer, B.R.; Wilson, D.M.; Dean, R.T. Tc-99m 1666: Development of a technetium-99m-labeled VIP-receptor imaging agent. J. Nucl. Med., 1998, 39, 225P.
50. Reubi, J.C. Regulatory peptide receptors as molecular targets for cancer diagnosis and therapy. Q. J. Nucl. Med., 1997, 41, 63-70.
51. Reubi, J.C. In vitro identification of vasoactive-intestinal-peptide receptors in human tumors - implications for tumor imaging. J. Nucl. Med., 1995, 36, 1846-1853.
52. Langer, M.; Beck-Sickinger, A.G. Peptides as carrier for tumor diagnosis and treatment. Curr. Med. Chem. Anticancer Agents, 2001, 1, 71-93.
53. Vincent, J.P. Neurotensin receptors: binding properties, transduction pathways, and structure. Cell Mol. Neurobiol., 1995, 15, 501- 512.
54. Reubi, J.C.; Waser, B.; Schaer, J.C.; Laissue, J.A. Neurotensin receptors in human neoplasms: high incidence in Ewing's sarcomas. Int. J. Cancer, 1999, 82, 213-218.
55. Reubi, J.C.; Waser, B.; Friess, H.; Buchler, M.; Laissue, J. Neurotensin receptors: a new marker for human ductal pancreatic adenocarcinoma. Gut, 1998, 42, 546-550.
56. Haberkorn, U.; Eisenhut, M.; Altmann, A.; Mier, W. Endoradiotherapy with peptides - status and future development. Curr. Med. Chem., 2008, 15, 219-234.
57. 99mTc-NT-XI, evaluated in ductal pancreatic adenocarcinoma patients. J. Nucl. Med., 2003, 44, 1649-1654.
58. Garcia-Garayoa, E.; Maes, V.; Blauenstein, P.; Blanc, A.; Hohn, A.; Tourwé, D.; Schubiger, P.A. Double-stabilized neurotensin analogues as potential radiopharmaceuticals for NTR-positive tumors. Nucl. Med. Biol., 2006, 33, 495-503.
59. Spindel, E.R.; Giladi, E.; Segerson, T.P.; Nagalla, S. Bombesin-like peptides of ligands and receptors. Rec. Progr. Horm. Res., 1993, 48, 365-391.
60. Nagalla, S.R.; Barry, B.J.; Creswick, K.C.; Eden, P.; Taylor, J.T.; Spindel, E.R. Cloning of a receptor for amphibian [Phe13]bombesin distinct from the receptor for gastrin-releasing peptide: identification of a fourth bombesin receptor subtype (BB4). Proc. Natl. Acad. Sci. U. S. A., 1995, 92, 6205-6209.
61. Schally, A.V.; Nagy, A. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. Eur. J. Endocrinol., 1999, 141, 1-14.
62. Reubi, J.C.; Waser, B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur. J. Nucl. Med. Mol. Imaging, 2003, 30, 781-793.
63. Van de Wiele, C.V.; Dumont, F.; Vanden Broecke, R.; Oosterlinck, W.; Cocquyt, V.; Serreyn, R.; Peers, S.; Thornback, J.; Slegers, G.; Dierckx, R.A. Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study. Eur. J. Nucl. Med., 2000, 27, 1694-1699.
64. 99mTc-RP527, a gastrin-releasing peptide (GRP) agonist for the visualization of GRP receptor-expressing malignancies. J. Nucl. Med., 2001, 42, 1722-1727.
65. 99mTc]Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging. Eur. J. Nucl. Med. Mol. Imaging, 2003, 30, 247-258.
66. 99mTc-labeling and in vivo studies of a bombesin analogue with a novel water-soluble dithiadiphosphine-based bifunctional chelating agent. Bioconjugate Chem., 1999, 10, 254-260.
67. 99mTc-labelled bombesin-like peptide. Cancer Biother. Radiopharm., 2002, 17, 317-326.
68. Lin, K.S.; Luu, A.N.; Baidoo, K.E.; Pili, R.; Carducci, M.A.; Wagner, H.N.J. In Technetium, rhenium, and other metals in chemistry and nuclear medicine 6. Nicolini M., Mazzi U., Eds., SGEditoriali: Padova, 2002, 363-367.
69. Okarvi, S.M.; Al-Jammaz, I. Synthesis, radiolabelling and biological characteristics of a bombesin peptide analog as a tumor imaging agent. Anticancer Res., 2003, 23, 2745-2750.
70. 99mTc-N(3)SX- BBN [7-14] NH(2): an in vitro/in vivo structure-activity relationship study where X = 0-, 3-, 5-, 8-, and 11-carbon tethering moieties. Bioconjugate Chem., 2003, 14, 93-102.
71. Weide, T.; Modlinger, A.; Kessler, H. Spatial screening for the identification of the bioactive conformation of integrin ligands. Top. Curr. Chem., 2007, 272, 1-50.
72. Knight, L.C. Radiolabeled peptide ligands for imaging thrombi and emboli. Nucl. Med. Biol., 2001, 28, 515-526.
73. 99mTc-RP128 as a potential inflammation imaging agent: human dosimetry and first clinical results. J. Nucl. Med., 2001, 42, 154-161.
74. Brooks, P.C. Role of integrins in angiogenesis. Eur. J. Cancer, 1996, 32A, 2423-2429.
75. Fiedler, W.; Graeven, U.; Ergun, S.; Verago, S.; Kilic, N.; Stockschlader, M.; Hossfeld, D.K. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood, 1997, 89, 1870-1875.
76. Aumailley, M.; Gurrath, M.; Muller, G.; Calvete, J.; Timpl, R.; Kessler, H. Arg-Gly-Asp constrained within cyclic pentapeptides - Strong and selective inhibitors of cell-adhesion to vitronectin and laminin fragment P1. FEBS Lett., 1991, 291, 50-54.
77. 99mTclabelled cyclic RGD pepticle for imaging the alpha-v-beta-3 expression. Nuklearmedizin, 2004, 43, 26-32.
78. 99mTc]HYNIC-RGD for imaging integrin alpha-vbeta- 3 expression. Nucl. Med. Biol., 2006, 33, 945-952.
79. Sivolapenko, G.B.; Skarlos, D.; Pectasides, D.; Stathopoulou, E.; Milonakis, A.; Sirmalis, G.; Stuttle, A.; Courtenay-Luck, N.S.; Konstantinides, K.; Epenetos, A.A. Imaging of metastatic melanoma utilising a technetium-99m labelled RGD-containing synthetic peptide. Eur. J. Nucl. Med., 1998, 25, 1383-1389.
80. Mitra, A.; Nan, A.; Papadimitriou, J.C.; Ghandehari, H.; Line, B.R. Polymer-peptide conjugates for angiogenesis targeted tumor radiotherapy. Nucl. Med. Biol., 2006, 33, 43-52.
81. Miao, Y.B.; Whitener, D.; Feng, W.W.; Owen, N.K.; Cheng, J.Q.; Quinn, T.P. Evaluation of the human melanoma targeting properties of radiolabeled alpha-melanocyte stimulating hormone peptide analogues. Bioconjug. Chem., 2003, 14, 1177-1184.
82. 111In-DTPA-labeled analogs of alpha-melanocyte-stimulating hormone for melanoma targeting: receptor-binding in vitro and in vivo. Int. J. Cancer, 1994, 58, 749-755.
83. 188Re-labeled linear alpha-melanocyte stimulating hormone analogs for specific melanoma targeting. Nucl. Med. Biol., 1999, 26, 687-693.
84. 99mtechnetium-labeled cyclic alpha- melanocyte-stimulating hormone peptide analogues. Cancer Res., 2000, 60, 5649-5658.
85. 188Re-labeled alpha-melanocyte stimulating hormone peptide analogs for melanoma therapy. Int. J. Cancer, 2002, 101, 480-487.
86. Sivolapenko, G.B.; Douli, V.; Pectasides, D.; Skarlos, D.; Sirmalis, G.; Hussain, R.; Cook, J.; CourtenayLuck, N.S.; Merkouri, E.; Konstantinides, K.; Epenetos, A.A. Breast cancer imaging with radiolabelled peptide from complementarity-determining region of antitumour antibody. Lancet, 1995, 346, 1662-1666.
87. Seki, I.; Itaya, Y.; Hanaoka, K.; Yoshida, Y.; Shirakami, Y.; Katoazuma, M.; Mazzi, U. In Technetium, rhenium, and other metals in chemistry and nuclear medicine 5. Nicolini M., Mazzi U., Eds., SGEditoriali: Padova, 1999, 419-426.
88. Okarvi, S.M. Development of peptide-based radiopharmaceuticals as tumor imaging agents. J. Nucl. Med., 2002, 43, 369P.
89. Reubi, J.C. Neuropeptide receptors in health and disease: the molecular- basis for in vivo imaging. J. Nucl. Med., 1995, 36, 1825- 1835.
90. Hennig, I.M.; Laissue, J.A.; Horisberger, U.; Reubi, J.C. Substance- P receptors in human primary neoplasms: tumoral and vascular localization. Int. J. Cancer, 1995, 61, 786-792.
91. van Hagen, P.M.; Breeman, W.A.P.; Reubi, J.C.; Postema, P.T.E.; vanden Anker Lugtenburg, P.J.; Kwekkeboom, D.J.; Laissue, J.; Waser, B.; Lamberts, S.W.J.; Visser, T.J.; Krenning, E.P. Visualization of the thymus by substance P receptor scintigraphy in man. Eur. J. Nucl. Med., 1996, 23, 1508-1513.
92. Gotthardt, M.; Fischer, M.; Naeher, I.; Holz, J.B.; Jungclas, H.; Fritsch, H.W.; Behe, M.; Goke, B.; Joseph, K.; Behr, T.M. Use of the incretin hormone glucagon-like peptide-1 (GLP-1) for the detection of insulinomas: initial experimental results. Eur. J. Nucl. Med. Mol. Imaging, 2002, 29, 597-606.
93. Reubi, J.C.; Gugger, M.; Waser, B.; Schaer, J.C. Y(1)mediated effect of neuropeptide Y in cancer: breast carcinomas as targets. Cancer Res., 2001, 61, 4636-4641.
94. Korner, M.; Waser, B.; Reubi, J.C. Neuropeptide Y receptor expression in human primary ovarian neoplasms. Lab. Invest., 2004, 84, 71-80.
95. Korner, M.; Waser, B.; Reubi, J.C. High expression of neuropeptide Y receptors in tumors of the human adrenal gland and extraadrenal paraganglia. Clin. Cancer Res., 2004, 10, 8426-8433.
96. 99mTc-labeled neuropeptide Y analogues as potential tumor imaging agents. Bioconjugate Chem., 2001, 12, 1028-1034.
97. Zaidi, M.; Moonga, B.S.; Bevis, P.J.R.; Bascal, Z.A.; Breimer, L.H. The calcitonin gene peptides: biology and clinical relevance. Crit. Rev. Clin. Lab. Sci., 1990, 28, 109-174.
98. Mammen, M.; Choi, S.K.; Whitesides, G.M. Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors. Angew. Chem. Int. Ed., 1998, 37, 2755-2794.
99. Vagner, J.; Xu, L.P.; Handl, H.L.; Josan, J.S.; Morse, D.L.; Mash, E.A.; Gillies, R J.; Hruby, V.J. Heterobivalent ligands crosslink multiple cell-surface receptors: the human melanocortin-4 and delta-opioid receptors. Angew. Chem.-Int. Edit., 2008, 47, 1685- 1688.
100. 99mTc-labeled divalent and tetravalent CC49 single-chain Fv's: novel imaging agents for rapid in vivo localization of human colon carcinoma. J. Nucl. Med., 2001, 42, 1519-1527.
101. 99mTc-labeled cyclic arginine-glycine-aspartic (RGD) dimers with triglycine linkers. J. Med. Chem., 2008, 51, 7980-7990.
102. Dijkgraaf, I.; John A.W.; Kruijtzer, J.A.W.; Liu, S.; Soede, A.; Oyen, W.J.G.; Corstens,F.H.M.; Liskamp, R.M.J.; Boerman, O.C. Improved targeting of the alpha(v)beta(3) integrin by multimerization of RGD peptides. Eur. J. Nucl. Med. Mol., Imaging, 2007, 34, 267-273.
103. 99mTc-labeled cyclic RGD tetramer for noninvasive imaging integrin alpha(v)beta3-positive breast cancer. Bioconjug. Chem., 2007, 18, 438-446.
104. 18F-labeled dimeric RGD peptide. Mol. Imaging, 2005, 3, 96-104.
105. Poethko, T.; Thumshirn, G.; Hersel, U.; Rau, F.; Haubner, R.; Schwaiger, M. Improved tumor uptake, tumor retention and tumor/ background ratios of pegulated RGD multimers. J. Nucl. Med., 2003, 44, 46P.
106. Reubi, J.C. In Radionuclide peptide cancer therapy. Chinol M., Paganelli G., Eds., Taylor & Francis: New York (NY) 2006, 31-39.
107. 99mTc labeling of highly potent small peptides. Bioconjug. Chem., 1997, 8, 621-636.
108. Liu, S.; Edwards, D.S. 99mTc-labelled small peptides as diagnostic radiopharmaceuticals. Chem. Rew., 1999, 99, 2235-2268.
109. Fichna J.; Janecka, A. Synthesis of Target-Specific Radiolabeled Peptides for Diagnostic Imaging. Bioconjug. Chem., 2003, 14, 3- 17.
110. Liu, S. The role of coordination chemistry in the development of target-specific radiopharmaceuticals. Chem. Soc. Rev., 2004, 33, 445-461.
111. Liu, S. Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides. Adv. Drug Deliv. Rev., 2008, 60, 1347-1370.
112. 2(cyclam)](PF6) (cyclam = 1,4,8,11- tetraazacyclotetradecane). Inorg. Chem., 1992, 31, 2595-2598.
113. 99mTc]TRODAT-1 as dopamine transporter imaging agents. J. Med. Chem., 1998, 41, 428-436.
114. Miao, Y., Quinn, T.P. Alpha-melanocyte stimulating hormone peptide-targeted melanoma imaging. Front. Biosci., 2007, 12, 4514-4524.
115. 99mTc]technetium depreotide: a somatostatin receptor binding tumor imaging agent. J. Med. Chem., 2007, 50, 4295-4303.
116. 2-phosphino-amido ligand. Inorg. Chem., 1995, 34, 1779-1787.
117. 2. Inorg. Chem., 1997, 36, 1786-1791.
118. Smith, K.J.; Katti, K.V.; Volkert, W.A.; Barbour, L.J. Syntheses and characterization of chemically flexible, water-soluble dithio-bis(phosphine) compounds: Systematic investigation of the effect of chain length on the coordination chemistry of rhenium(v). Inorg. Chem., 1997, 36, 3928-3935.
119. 99mTc-Labeling, and in vitro characterization of HYNIC and N(3)S modified RC-160 and [Tyr3]Octreotide. Bioconjug. Chem., 1999, 10, 431-438.
120. 99TcO] Apcitide: a technetium labeled peptide. Inorg. Chem., 2004, 43, 2867-2875.
121. 99mTc-P829 in patients with Graves' disease. J. Nucl. Med., 2003, 44, 1547-1555.
122. 3-annexin V: influence of the chelate on in vitro and in vivo properties in mice. Nucl. Med. Biol., 2006, 33, 135-144.
123. 99mTclabeled HYNIC and N2S2 chelate conjugated to the antimicrobial peptide UBI 29-41. Nucl. Med. Biol., 2004, 31, 503-509.
124. Blankenberg, F.; Ohtsuki, K.; Strauss, H.W. Dying a thousand deaths - Radionuclide imaging of apoptosis. Q. J. Nucl. Med., 1999, 43, 170-176.
125. 99mTc-labeled vasoactive intestinal peptide receptor agonist: functional studies. J. Nucl. Med., 1999, 40, 352-360.
126. Baidoo, K.E.; Lin, K.S.; Zhan, Y.; Finley, P.; Scheffel, U.; Wagner, H.N. Design, synthesis, and initial evaluation of high-affinity technetium bombesin analogues. Bioconjug. Chem., 1998, 9, 218-225.
127. 111In]DOTA-tate. Eur. J. Nucl. Med. Mol. Imaging, 2006, 33, 831-840.
128. 99mTc-labeled minigastrin analogs. J. Nucl. Med., 2005, 46, 1727-1736.
129. Abrams, M.J.; Juweid, M.; Tenkate, C.I.; Schwartz, D.A.; Hauser, M.M.; Gaul, F.E.; Fuccello, A.J.; Rubin, R.H.; Strauss, H.W.; Fischman, A.J. Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. J. Nucl. Med., 1990, 31, 2022-2028.
130. 99mTc-labeling of small biomolecules. Top. Curr. Chem., 2005, 252, 117-153.
131. 99mTc: a reflection on technetium core structures and a strategy for new chelate design. Nucl. Med. Biol., 2005, 32, 1-20.
132. 99mTc using aminocarboxylates as coligands. Bioconjugate Chem., 1996, 7, 63-71.
133. 99mTc-EDDA/HYNIC-TOC). J. Labelled Compd. Radiopharm., 2003, 46, 307-318.
134. 99mTc. Bioconjug. Chem., 1997, 8, 146-154.
135. 99mTc. Bioconjug. Chem., 1997, 8, 155-160.
136. 99mTc-labeling of hydrazino nicotinamide-modified biologically active molecules using imine-N-containing heterocycles as coligands. Bioconjug. Chem., 1998, 9, 583-595.
137. 99mTc]Tricine: a useful precursor complex for the radiolabeling of hydrazinonicotinate protein conjugates. Bioconjug. Chem., 1995, 6, 635-638.
138. 99mTc-labeled bioconjugates. Bioconjug. Chem., 2000, 11, 113-117.
139. Line, B.R.; Crane, P.; Lazewatsky, J.; Barrett, J.A.; Cloutier, D.; Kagan, M.; Lukasiewicz, R.; Holmes, R.A. Phase I trial of DMP 444, a new thrombus imaging agent. J. Nucl. Med., 1996, 37, 117P.
140. Line, B.R.; Seabold, J.E.; Edell, S.L.; Weiland, F.L.; Heit, J.A.; Crane, P.D.; Widner, P.J.; Haber, S.B. Preliminary diagnostic results with DMP 444, a new thrombus imaging agent. J. Nucl. Med., 1998, 39, 969.
141. Mitchel, J.; Waters, D.; Lai, T. J.; White, M.; Alberghini, T.; Salloum, A.; Knibbs, D.; Li, D.D.; Heller, G.V. Identification of coronary thrombus with a IIb/IIIa platelet inhibitor radiopharmaceutical, technetium-99m DMP-444: a canine model. Circulation, 2000, 101, 1643-1646.
142. Klem, J.A.; Schaffer, J.V.; Crane, P.D.; Barrett, J.A.; Henry, G.A.; Canestri, L.; Ezekowitz, M.D. Detection of deep venous thrombosis by DMP 444, a platelet IIb/IIIa antagonist: a preliminary report. J. Nucl. Cardiol., 2000, 7, 359-364.
143. Liu, S.; Edwards, D.S.; Harris, A.R.; Ziegler, M.C.; Poirier, M.J.; Ewels, B.A.; Diluzio, W.R.; Hui, P. Towards developing a non- SnCl2 formulation for RP444, a new radiopharmaceutical for thrombus imaging. J. Pharm. Sci., 2001, 90, 114-123.
144. 99mTc-labeling of small biomolecules. Bioconjug. Chem., 2003, 14, 720-727.
145. 99mTc-EDDA/HYNIC-[Lys 3]-bombesin for imaging gastrin-releasing peptide receptor-positive tumours. Nucl. Med. Commun., 2006, 27, 371-376.
146. 99mTc-EDDA-HYNICD- Phe1, Tyr3]-octreotide, a somatostatin analog for tumor diagnosis. J. Pharm. Sci., 2004, 93, 2497-2506.
147. 99mTc-HYNICTyr- octreotide scintigraphy in a patient affected by sarcoidosis with lung and joints involvement and secondary Sjogren's syndrome treated with infliximab: case report. Eur. Rev. Med. Pharmacol. Sci., 2008, 12, 127-130.
148. 99mTc-EDDA/HYNIC (D)Glu-octagastrin for scintigraphy of medullary thyroid carcinoma. Cancer Biother. Radiopharm., 2007, 22, 613-628.
149. 99mTc-EDDA/HYNIC-TOC in patients with medullary thyroid carcinoma. Eur. J. Nucl. Med. Mol. Imaging., 2007, 34, 1635-1645.
150. 99mTc-EDDA/HYNIC-TOC scintigraphy in oncological diagnostics: a pilot study. Cancer Biother. Radiopharm., 2004, 19, 261-270.
151. 4N)]. Inorg. Chim. Acta, 1996, 252, 421-426.
152. 4N)]. Inorg. Chim. Acta, 1996, 252, 427-430.
153. Rose, D.J.; Maresca, K.P.; Nicholson, T.; Davison, A.; Jones, A.G.; Babich, J.; Fischman, A.; Graham, W.; DeBord, J.R.D.; Zubieta, J. Synthesis and characterization of organohydrazino complexes of technetium, rhenium, and molybdenum with the {M(eta(1)-H(x)NNR)(eta(2)-H(y)NNR)} core and their relationship to radiolabeled organohydrazine-derivatized chemotactic peptides with diagnostic applications. Inorg. Chem., 1998, 37, 2701-2716.
154. 2]. Inorg. Chim. Acta, 1998, 271, 191-194.
155. 3)]. Inorg. Chim. Acta, 1998, 279, 206-209.
156. Hirsch-Kuchma, M.; Nicholson, T.; Davison, A.; Davis, W.M.; Jones, A.G. Synthesis and characterization of rhenium(III) and technetium(III) organohydrazide chelate complexes. Reactions of 2-hydrazinopyridine with complexes of rhenium and technetium. Inorg. Chem., 1997, 36, 3237-3241.
157. Hirsch-Kuchma, M.; Nicholson, T.; Davison, A.; Davis, W.M.; Jones, A.G. The synthesis and characterization of technetium and rhenium hydrazinopyrimidine chelate complexes. J. Chem. Soc., Dalton Trans., 1997, 3185-3188.
158. Hirsch-Kuchma, M.; Nicholson, T.; Davison, A.; Jones, A. G. Group 7 'organohydrazide' chemistry: classification of ligand type based on crystal structural data. J. Chem. Soc. Dalton Trans., 1997, 3189-3192.
159. Babich, J.W.; Solomon, H.; Pike, M.C.; Kroon, D.; Graham, W.; Abrams, M.J.; Tompkins, R.G.; Rubin, R.H.; Fischman, A.J. Technetium-99m-labeled hydrazino nicotinamide derivatized chemotactic peptide analogs for imaging focal sites of bacterial infection. J. Nucl. Med., 1993, 34, 1964-1974.
160. Ono, M.; Arano, Y.; Uehara, T.; Fujioka, Y.; Ogawa, K.; Namba, S.; Mukai, T.; Nakayama, M.; Saji, H. Intracellular metabolic fate of radioactivity after injection of technetium-99m-labeled hydrazino nicotinamide derivatized proteins. Bioconjug. Chem., 1999, 10, 386-394.
161. 99mTc-labeled polypeptides with low in vivo protein binding. Nucl. Med. Biol., 2001, 28, 215-224.
162. Decristoforo, C.; Mather, S.J. 99m-Technetium-labelled peptide- HYNIC conjugates: effects of lipophilicity and stability on biodistribution. Nucl. Med. Biol., 1999, 26, 389-396.
163. 99mTc- HYNIC-octreotide scintigraphy and CT/MRI in patients with thyroid-associated orbitopathy: the importance of the lacrimal gland. Eur. J. Nucl. Med. Mol. Imaging, 2003, 30, 1155-1159.
164. 99mTc-TATE in identifying sites of disease in patients with proven GEP NETs. J. Nucl. Med., 2008, 49, 1060-1065.
165. 2 with favorable properties for SPECT imaging of colon cancer. Bioconjug. Chem., 2008, 19, 1170-1178.
166. 99mTc-HYNIC annexin V uptake to microvessel density, FasL and MMP-9 expression, and the number of tumourinfiltrating lymphocytes in head and neck carcinoma. Eur. J. Nucl. Med. Mol. Imaging, 2004, 31, 1016-1021.
167. 99mTc-HYNIC-annexin B1 as a novel radioligand for apoptosis imaging. Apoptosis, 2008, 134, 600-608.
168. 99mTc-labeling and in vitro and in vivo evaluation of HYNIC- and (Nalpha-His)acetic acid-modified [D-Glu1]- minigastrin. Bioconjug. Chem., 2004, 15, 864-871.
169. 99mTc-labeled cyclic RGDfK dimer. Bioconjug. Chem., 2006, 17, 1499-1507.
170. Su, Z.F.; Liu, G.; Gupta, S.; Zhu, Z.; Rusckowski, M.; Hnatowich, D.J. In vitro and in vivo evaluation of a technetium-99m-labeled cyclic RGD peptide as a specific marker of alpha(v)beta(3) integrin for tumor imaging. Bioconjug. Chem., 2002, 13, 561-570.
171. 99mTc-labeled cyclic RGDfK tetramer. Nucl. Med. Biol., 2008, 35, 111-121.
172. 99mTc labelled epidermal growth factor. Nucl Med Commun., 2005, 26, 147-153.
173. 99mTc] HYNIC-hEGF, a potential agent for imaging of EGF receptors in vivo: preparation and pre-clinical evaluation. Oncol Rep. 2005, 13, 1169-1175.
174. Blankenberg, F.G.; Mandl, S.; Cao, Y.A.; O'Connell-Rodwell, C.; Contag, C.; Mari, C.; Gaynutdinov, T.I.; Vanderheyden, J.L.; Backer, M.V.; Backer, J.M. Tumor imaging using a standardized radiolabeled adapter protein docked to vascular endothelial growth factor. J. Nucl. Med., 2004, 45, 1373-1380.
175. 99mTc-labeled FGF-1 targeting in rats. Nucl. Med. Biol., 2000, 27, 407-414.
176. 99mTc-HYNICinterleukin- 12, a new specific radiopharmaceutical for imaging T lymphocytes. Eur. J. Nucl. Med. Mol. Imaging, 2006, 33, 474-482.
177. 99mTcinterleukin- 8 in rabbits. J. Nucl. Med., 2001, 42, 917-923.
178. 99mTc-labeled interleukin-8 in experimental inflammation and infection. J. Nucl. Med., 2003, 44, 1502-1509.
179. Fischman, A.J.; Rauh, D.; Solomon, H.; Babich, J.W.; Tompkins, R.G.; Kroon, D.; Strauss, H.W.; Rubin, R.H. In vivo bioactivity and biodistribution of chemotactic peptide analogs in non-human primates. J. Nucl. Med., 1993, 34, 2130-2134.
180. 4]- in aqueous solution and its reaction with a bifunctional ligand. J. Am. Chem. Soc., 1998, 120, 7987 -7988.
181. Waibel, R.; Alberto, R.; Willuda, J.; Finnern, R.; Schibli, R.; Stichelberger, A.; Egli, A.; Abram, U.; Mach, J.P.; Pluckthun, A.; Schubiger, P.A. Stable one-step technetium-99m labeling of His tagged recombinant proteins with a novel Tc(I)-carbonyl complex. Nat. Biotechnol., 1999, 17, 897-901.
182. 99mTc-aquaion labels peptide to an unprecedented high specific activity. J. Nucl. Med., 1999, 40, 1913- 1917.
183. 99mTc(I)-tricarbonyl complexes: a hint for the future functionalization of biomolecules. Bioconjugate Chem., 2000, 11, 345-351.
184. +(M = Re, Tc-99, Tc-99m) complexes with tridentate amine ligands. Synth. React. Inorg. Met. Org. Nano Met. Chem., 2005, 35, 27-34.
185. +. Chem. Eur. J., 2003, 9, 2053-2061.
186. +. Org. Biomol. Chem., 2004, 2, 2593-2603.
187. 99mTc-carbonyls. Biopolymers, 2004, 76, 324-333.
188. Bartholoma, M.; Valliant, J.; Maresca, K.P.; Babichc, J.; Zubieta, J. Single amino acid chelates (SAAC): a strategy for the design of technetium and rhenium radiopharmaceuticals. Chem. Commun., 2009, 7, 493-512.
189. Stephenson, K.A.; Banerjee, S.R.; Sogbein, O.O.; Levadala, M.K.; McFarlane, N.; Boreham, D.R.; Maresca, K.P.; Babich, J.W.; Zubieta, J.; Valliant, J.F. A new strategy for the preparation of peptidetargeted technetium and rhenium radiopharmaceuticals. The automated solid-phase synthesis, characterization, labeling, and screening of a peptide-ligand library targeted at the formyl peptide receptor. Bioconjug. Chem., 2005, 16, 1189-1195.
190. 3(+1) core (M = Tc and Re): syntheses, characterization, biotinidase stability, and avidin binding. Bioconjug. Chem., 2006, 17, 579 -589.
191. 3](+) (M = Re, Tc) directed towards radiopharmaceutical application. Coord. Chem. Rev., 1999, 190/192, 901-919.
192. Alberto, R. New organometallic technetium complexes for radiopharmaceutical imaging. Top. Curr. Chem., 2005, 252, 1-44.
193. + chemistry: a promising new concept for SPET? Eur. J. Nucl. Med. Mol. Imaging, 2003, 30, 1299-1302.
194. +. J. Am. Chem. Soc., 2001, 123, 3135-3136.
195. Schibli, R.; Schubiger, P.A. Current use and future potential of organometallic radiopharmaceuticals. Eur. J. Nucl. Med. Mol. Imaging, 2002, 29, 1529-1542.
196. 3 bombesin analogues. Nucl. Med. Biol. 2007, 34, 17-28.
197. 99mTc(CO)3]-labeled bombesin analogues for improved targeting of gastrin-releasing peptide receptor-positive tumors. Bioconjug. Chem., 2008, 19, 2432-2439.
198. 99mTc-labeled ubiquicidin 29-41 antimicrobial peptide for the scintigraphic detection of mediastinitis after cardiac surgery. Arch Med Res., 2008, 39, 768-774.
199. +: effect of cyclization on tumor-seeking properties. J. Biol. Inorg. Chem., 2008, 13, 449-459.
200. 99mTc-labeled glucosamino RGD and effect of paclitaxel therapy. J. Nucl. Med., 2006, 47, 2000-2007.
201. 99mTc]cRGD peptides labeled using different novel Tc-cores. Q. J. Nucl. Med. Mol. Imaging., 2007, 51, 33-41.
202. Blankenberg, F.; Tait, J.; Blankenberg, T.; Post, A.; Strauss, W. Imaging macrophages and the apoptosis of granulocytes in a rodent model of subacute and chronic abscesses with radiolabeled monocyte chemotactic peptide-1 and annexin V. Eur. J. Nucl. Med. Mol. Imag., 2001, 28, 1384-1393.
203. 99mTc-labeled neuropeptides using stabilized peptide analogues. Cancer Biother. Radiopharm., 2004, 19, 181-188.
204. 99mTc-labeled neurotensin peptide 8-13. Nucl. Med. Biol., 2006, 33, 505-512.
205. 99mTc-labeled neurotensin analogues with optimized biodistribution properties. J. Med. Chem., 2006, 49, 1833-1836.
206. Duatti, A.; Marchi, A.; Pasqualini, R. Formation of the Tc≡N multiple bond from the reaction of ammonium pertechnetate with Smethyl dithiocarbazate and its application to the preparation of technetium-99m radiopharmaceuticals. J. Chem. Soc. Dalton Trans., 1990, 3729-3733.
207. Boschi, A.; Duatti, A.; Uccelli, L. Development of technetium-99m and rhenuim-188 radiopharmaceuticals containg a terminal metalnitrido multiple bond for diagnosis and therapy. Top. Curr. Chem., 2005, 252, 85-115.
208. Pasqualini, R.; Duatti, A.; Bellande, E.; Comazzi, V.; Brucato, V.; Hoffschir, D.; Fagret, D.; Comet, M. Bis(dithiocarbamato) nitrido technetium-99m radiopharmaceuticals: a class of neutral myocardial imaging agents. J. Nucl. Med., 1994, 35, 334-341.
209. 2] [L5= 2- (diphenylphosphino)propanethiolato]. Inorg. Chem., 1999, 38, 4473-4479.
210. 99mTc radiopharmaceutical with phosphino-thiol ligands showing transient heart uptake. J. Nucl. Med. Biol., 2000, 27, 369-374.
211. Bolzati, C.; Boschi, A.; Duatti, A.; Prakash, S.; Uccelli, L.; Refosco, F.; Tisato, F.; Bandoli, G. Geometrically controlled selective formation of nitrido technetium(v) asymmetrical heterocomplexes with bidentate ligands. J. Am. Chem. Soc., 2000, 122, 4510- 4511.
212. 2+ (PXP = Diphosphine ligand). A novel tool for the selective labeling of small molecules. J. Am. Chem. Soc., 2002, 124, 11468-11479.
213. 2+ (PXP = Diphosphine ligand). Bioconjug. Chem., 2001, 12, 1035-1042.
214. 99Tc, Re; DTC = dithiocarbammate; PNP= heterodiphosphine). Eur. J. Inorg. Chem., 2004, 1902-1913.
215. 2+ metal fragments (M = Tc, Re; PXP= diphosphine ligand). Inorg. Chem., 2004, 43, 8617-8625.
216. Bolzati, C.; Malagò, E.; Boschi, A.; Cagnolini, A.; Porchia, M.; Bandoli, G. Symmetric bis-substituted and asymmetric monosubstituted nitridotechnetium complexes with heterofunctionalized phosphinothiolate ligands. New J. Chem., 1999, 23, 807-809.
217. 99mTc compounds as potential brain imaging agents. Bioconjug. Chem., 2006, 17, 419-428.
218. Bolzati, C.; Cavazza-Ceccato, M.; Agostini, S.; Tisato, F.; Bandoli, G. Technetium and rhenium in five-coordinate symmetrical and dissymmetrical nitrido complexes with alkyl phosphino-thiol ligands. Synthesis and structural characterization. Inorg. Chem., 2008, 47, 11972-11983.
219. 99mTc heterocomplexes as heart imaging agents with improved biological properties. Nucl. Med. Commun., 2002, 23, 689-693.
220. 99mTcnitride heterocomplexes showing high heart uptake and improved imaging properties. J. Nucl. Med., 2003, 44, 806-814.
221. Bolzati, C.; Benini, E.; Cazzola, E.; Jung, C.; Tisato, F.; Refosco, F.; Pietzsch, H. J.; Spies, H.; Uccelli, L.; Duatti, A. Synthesis, characterization, and biological evaluation of neutral nitrido technetium(V) mixed ligand complexes containing dithiolates and aminodiphosphines. A novel system for linking technetium to biomolecules. Bioconjug. Chem., 2004, 15, 628-637.
222. 99mTc: a model for a novel class of cancer imaging agents. Bioorg. Med. Chem. Lett., 2000, 10, 1397- 1400.
223. 2+ metal fragment: a technetium-nitrido synthon for use with biologically active molecules. The N-(2-methoxyphenyl)piperazyl-cysteine analogues as examples. Bioconjug. Chem., 2003, 14, 1231-1242.
224. 99mTc- heterocomplexes as potential imaging agents for benzodiazepine receptors. Bioconjug. Chem., 2003, 14, 1279- 1288.
225. 2+ metal fragment. Nucl. Med. Biol., 2007, 34, 511-522.
226. Faintuch, B.L.; Teodoro, R.; Duatti, A.; Muramoto, E.; Faintuch, S.; Smith, C.J. Radiolabeled bombesin analogs for prostate cancer diagnosis: preclinical studies. Nucl. Med. Biol., 2008, 35, 401-411.
227. Spies, H.; Glaser, M.; Pietzsch, H.J.; Hahn, F.E.; Kintzel, O.; Lügger, T. Trigonal-bipyramidale Technetium- und Rhenium- Komplexe mit vierzähnigen tripodalen NS3 Liganden. Angew. Chem., 1994, 106, 1416-1419.
228. 3 ligand. Inorg. Chim. Acta, 1995, 240, 465-478.
229. Spies, H.; Fietz, Th.; Glaser, M.; Pietzsch, H.J.; Johannsen, B. In 4th Int. Symp. on Technetium in chemistry and nuclear medicine. Nicolini M., Bandoli G., Mazzi U., Eds., SGEditoriali: Padova (Italy), 1996, 243-246.
230. Pietzsch, H.J.; Gupta, A.; Syhre, R.; Leibnitz, P.; Spies, H. Mixesligand technetium(III) complexes with tetradentate/monodentate NS3/isocyanide coordination: a new nonpolar technetium chelate system for the design of neutral and lipophilic complexes stable in vivo. Bioconjug. Chem., 2001, 12, 538-544.
231. 188Re analogues. Bioconjug. Chem., 2004, 15, 856-863.
232. Schiller, E.; Seifert, S.; Tisato, F.; Refosco, F.; Kraus, W.; Spies, H.; Pietzsch, H.J. Mixed-ligand rhenium-188 complexes with tetradentate/monodentate NS3/P ('4+1') coordination: relation of structure with antioxidation stability. Bioconjug. Chem., 2005, 16, 634-643.
233. 1A receptor and the alpha1-adrenergic receptor. Nucl. Med. Biol., 2002, 29, 389-398.
234. 99mTc(III) '4 + 1' bombesin(7-14) conjugates: synthesis, radiolabeling, and in vitro/in vivo studies. Bioconjug. Chem., 2007, 18, 1651-1661.